Synlogic, Inc. (0A8U.L)
| Chiusura precedente | 1,0815 |
| Aperto | 1,0748 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,0748 - 1,0748 |
| Intervallo di 52 settimane | 1,0748 - 1,0748 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,61 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9740 |
| Prossima data utili | 10 ago 2022 - 15 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced it will participate in the HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation 2022 Conference, in Bethesda, Maryland, June 25-26, 2022. Synlogic has been invited to present a poster to patients and families affected by ho
- GlobeNewswire
Synlogic Reminds Stockholders of 2022 Annual General Meeting Details
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reminded stockholders that it will hold its 2022 Annual General Meeting of Stockholders on June 9, 2022 at 9:00 A.M. ET. The Annual Meeting will be held in virtual format only via live audio webcast. Synlogic's stockholders of record as of April 12, 2022
- GlobeNewswire
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan designation for SYNB1618 for the treatment of phenylketonuria (PKU). Previously, the U.S. Food and Drug Administration (FDA) granted SYNB16
